XPO1-dependent nuclear export as a target for cancer therapy

Nancy G. Azizian; Nancy G. Azizian; Yulin Li; Yulin Li

doi:10.1186/s13045-020-00903-4

XPO1-dependent nuclear export as a target for cancer therapy

Nancy G. Azizian, Nancy G. Azizian, Yulin Li, Yulin Li

Experimental Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

106 Scopus citations

Abstract

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.

Original language	English (US)
Article number	61
Journal	Journal of Hematology and Oncology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/s13045-020-00903-4
State	Published - Jun 1 2020

Keywords

Cancer
CRM1
Nuclear export
Selective inhibitor of nuclear export (SINE)
Selinexor
XPO1

ASJC Scopus subject areas

Hematology
Molecular Biology
Oncology
Cancer Research

Access to Document

10.1186/s13045-020-00903-4

Cite this

@article{22e2693062954b7e8487669b77985a8f,

title = "XPO1-dependent nuclear export as a target for cancer therapy",

abstract = "Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.",

keywords = "Cancer, CRM1, Nuclear export, Selective inhibitor of nuclear export (SINE), Selinexor, XPO1",

author = "Azizian, {Nancy G.} and Azizian, {Nancy G.} and Yulin Li and Yulin Li",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = jun,

day = "1",

doi = "10.1186/s13045-020-00903-4",

language = "English (US)",

volume = "13",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - XPO1-dependent nuclear export as a target for cancer therapy

AU - Azizian, Nancy G.

AU - Li, Yulin

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.

AB - Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.

KW - Cancer

KW - CRM1

KW - Nuclear export

KW - Selective inhibitor of nuclear export (SINE)

KW - Selinexor

KW - XPO1

UR - http://www.scopus.com/inward/record.url?scp=85085910005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085910005&partnerID=8YFLogxK

U2 - 10.1186/s13045-020-00903-4

DO - 10.1186/s13045-020-00903-4

M3 - Review article

C2 - 32487143

AN - SCOPUS:85085910005

SN - 1756-8722

VL - 13

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 61

ER -

XPO1-dependent nuclear export as a target for cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this